$CRDF
Cardiff Oncology, Inc. Stock $crdf

$crdf Overview Financials Valuation SEC Filings Company Website

2019 Q1 Form 10-Q Financial Statement

#000162828019006051 Filed on May 07, 2019

Income Statement

Concept	2019 Q1	2018 Q1
Revenue	$62.02K	$100.1K
YoY Change	-38.06%	5.36%
Cost Of Revenue	$0.00	$366.3K
YoY Change	-100.0%	-40.57%
Gross Profit	$62.02K	-$266.2K
YoY Change	-123.3%	-48.94%
Gross Profit Margin	100.0%	-265.85%
Selling, General & Admin	$1.375M	$2.505M
YoY Change	-45.1%	-30.51%
% of Gross Profit	2217.29%
Research & Development	$2.649M	$1.884M
YoY Change	40.6%	-55.98%
% of Gross Profit	4270.49%
Depreciation & Amortization	$126.8K	$252.5K
YoY Change	-49.79%	-23.71%
% of Gross Profit	204.42%
Operating Expenses	$4.024M	$4.755M
YoY Change	-15.38%	-53.48%
Operating Profit	-$3.962M	-$4.655M
YoY Change	-14.89%	-54.03%
Interest Expense	$0.00	$24.24K
YoY Change	-100.0%	-81.36%
% of Operating Profit
Other Income/Expense, Net	$2.010K	$1.000K
YoY Change	101.0%
Pretax Income	-$3.900M	-$4.790M
YoY Change	-18.58%	-52.1%
Income Tax
% Of Pretax Income
Net Earnings	-$3.905M	-$4.786M
YoY Change	-18.42%	-52.14%
Net Earnings / Revenue	-6295.89%	-4779.68%
Basic Earnings Per Share	-$1.02	-$6.23
Diluted Earnings Per Share	-$1.02	-$6.23
COMMON SHARES
Basic Shares Outstanding	4.087M shares	769.0K shares
Diluted Shares Outstanding	4.087M shares	769.0K shares

Balance Sheet

Concept	2019 Q1	2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$11.30M	$6.700M
YoY Change	68.66%	-76.74%
Cash & Equivalents	$11.33M	$6.657M
Short-Term Investments
Other Short-Term Assets	$900.0K	$1.100M
YoY Change	-18.18%	37.5%
Inventory
Prepaid Expenses	$890.7K
Receivables	$115.7K	$114.3K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$12.34M	$7.840M
YoY Change	57.36%	-73.63%
LONG-TERM ASSETS
Property, Plant & Equipment	$293.4K	$2.224M
YoY Change	-86.81%	-37.66%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$87.07K	$345.3K
YoY Change	-74.78%	-45.08%
Total Long-Term Assets	$2.197M	$2.569M
YoY Change	-14.49%	-38.77%
TOTAL ASSETS
Total Short-Term Assets	$12.34M	$7.840M
Total Long-Term Assets	$2.197M	$2.569M
Total Assets	$14.53M	$10.41M
YoY Change	39.63%	-69.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$466.7K	$651.7K
YoY Change	-28.38%	-32.71%
Accrued Expenses	$2.022M	$1.685M
YoY Change	19.97%	-56.01%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due		$1.200M
YoY Change		-69.23%
Total Short-Term Liabilities	$3.285M	$3.854M
YoY Change	-14.77%	-56.98%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change		-100.0%
Other Long-Term Liabilities	$1.600M	$1.900M
YoY Change	-15.79%	18.75%
Total Long-Term Liabilities	$1.600M	$1.900M
YoY Change	-15.79%	-86.71%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.285M	$3.854M
Total Long-Term Liabilities	$1.600M	$1.900M
Total Liabilities	$4.847M	$5.729M
YoY Change	-15.4%	-75.35%
SHAREHOLDERS EQUITY
Retained Earnings	-$196.4M	-$177.7M
YoY Change	10.49%	12.4%
Common Stock	$7.906K	$5.883K
YoY Change	34.39%	89.9%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$9.686M	$4.679M
YoY Change
Total Liabilities & Shareholders Equity	$14.53M	$10.41M
YoY Change	39.63%	-69.32%

Cashflow Statement

Concept	2019 Q1	2018 Q1
OPERATING ACTIVITIES
Net Income	-$3.905M	-$4.786M
YoY Change	-18.42%	-52.14%
Depreciation, Depletion And Amortization	$126.8K	$252.5K
YoY Change	-49.79%	-23.71%
Cash From Operating Activities	-$3.360M	-$2.860M
YoY Change	17.48%	-67.35%
INVESTING ACTIVITIES
Capital Expenditures	$5.274K	$5.100K
YoY Change	3.41%	-55.47%
Acquisitions
YoY Change
Other Investing Activities		$0.00
YoY Change		-100.0%
Cash From Investing Activities	-$5.274K	-$10.00K
YoY Change	-47.26%	-100.19%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$3.242M	1.290M
YoY Change	151.34%	-906.25%
NET CHANGE
Cash From Operating Activities	-$3.360M	-2.860M
Cash From Investing Activities	-$5.274K	-10.00K
Cash From Financing Activities	$3.242M	1.290M
Net Change In Cash	-$123.1K	-1.580M
YoY Change	-92.21%	-57.75%
FREE CASH FLOW
Cash From Operating Activities	-$3.360M	-$2.860M
Capital Expenditures	$5.274K	$5.100K
Free Cash Flow	-$3.365M	-$2.865M
YoY Change	17.46%	-67.34%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2019Q1	dei	Amendment Flag AmendmentFlag	false
CY2019Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2019Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019Q1	dei	Document Period End Date DocumentPeriodEndDate	2019-03-31
CY2019Q1	dei	Document Type DocumentType	10-Q
CY2019Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001213037
CY2019Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	5245217	shares
CY2019Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2019Q1	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2019Q1	dei	Entity Registrant Name EntityRegistrantName	Trovagene, Inc.
CY2019Q1	trov	Class Of Warrant Or Right Number Exercised ClassOfWarrantOrRightNumberExercised	497313	shares
CY2019Q1	trov	Class Of Warrant Or Right Number Granted ClassOfWarrantOrRightNumberGranted	150065	shares
CY2018	trov	Class Of Warrant Or Right Term Of Outstanding Warrants Or Rights ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights	P4Y4M21D
CY2019Q1	trov	Class Of Warrant Or Right Term Of Outstanding Warrants Or Rights ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights	P4Y2M12D
CY2018Q4	trov	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights	8.91
CY2019Q1	trov	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights	9.02
CY2019Q1	trov	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Exercised ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised	6.60
CY2019Q1	trov	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Granted ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted	3.76
CY2018Q1	trov	Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment	0	USD
CY2019Q1	trov	Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment	1675000	USD
CY2019Q1	trov	Costof Issuanceof Common Stock Preferred Stockand Warrantsfor Clinical Trial Funding Commitment CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment	40000	USD
CY2018Q1	trov	Deemed Dividend Related To Beneficial Conversion Feature Of Preferred Stock DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock	0	USD
CY2019Q1	trov	Deemed Dividend Related To Beneficial Conversion Feature Of Preferred Stock DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock	268269	USD
CY2019Q1	trov	Discountof Issuanceof Common Stock Preferred Stockand Warrantsfor Clinical Trial Funding Commitment DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment	235640	USD
CY2018Q1	trov	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	0	USD
CY2019Q1	trov	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-186689	USD
CY2018Q1	trov	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	0	USD
CY2019Q1	trov	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-154058	USD
CY2019Q1	trov	Lessee Operating Lease Annual Rent Increase Percentage LesseeOperatingLeaseAnnualRentIncreasePercentage	0.03
CY2019Q1	trov	Lessee Operating Lease Liability Payments Net Of Sublease Income Due LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue	2300046	USD
CY2019Q1	trov	Lessee Operating Lease Liability Payments Net Of Sublease Income Due Year Five LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearFive	3423	USD
CY2019Q1	trov	Lessee Operating Lease Liability Payments Net Of Sublease Income Due Year Four LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearFour	5868	USD
CY2019Q1	trov	Lessee Operating Lease Liability Payments Net Of Sublease Income Due Year Three LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree	968165	USD
CY2019Q1	trov	Lessee Operating Lease Liability Payments Net Of Sublease Income Due Year Two LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo	941670	USD
CY2019Q1	trov	Lessee Operating Lease Liability Payments Net Of Sublease Income Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear	380920	USD
CY2018Q4	trov	Related Party Committed Expenditures RelatedPartyCommittedExpenditures	576000	USD
CY2018Q1	trov	Releaseofclinicaltrialfundingcommitmentforservicesreceived Releaseofclinicaltrialfundingcommitmentforservicesreceived	0	USD
CY2019Q1	trov	Releaseofclinicaltrialfundingcommitmentforservicesreceived Releaseofclinicaltrialfundingcommitmentforservicesreceived	70487	USD
CY2018Q4	trov	Servicereceivable Servicereceivable	0	USD
CY2019Q1	trov	Servicereceivable Servicereceivable	1604513	USD
CY2019Q1	trov	Servicereceivable Servicereceivable	1675000	USD
CY2019Q1	trov	Lessee Operating Lease Monthly Rent Payment LesseeOperatingLeaseMonthlyRentPayment	74000	USD
CY2019Q1	trov	Lessee Operating Lease Number Of Renewal Options LesseeOperatingLeaseNumberOfRenewalOptions	1	renewal_option
CY2019Q1	trov	Lessor Number Of Subleases LessorNumberOfSubleases	3	lease
CY2018Q4	trov	Operating Leases Future Minimum Payments Due Net Of Sublease Rentals OperatingLeasesFutureMinimumPaymentsDueNetOfSubleaseRentals	2500542	USD
CY2018Q4	trov	Operating Leases Future Minimum Payments Due Net Of Sublease Rentals Next Twelve Months OperatingLeasesFutureMinimumPaymentsDueNetOfSubleaseRentalsNextTwelveMonths	581416	USD
CY2018Q4	trov	Operating Leases Future Minimum Payments Net Of Sublease Rentals Due In Five Years OperatingLeasesFutureMinimumPaymentsNetOfSubleaseRentalsDueInFiveYears	3423	USD
CY2018Q4	trov	Operating Leases Future Minimum Payments Net Of Sublease Rentals Due In Four Years OperatingLeasesFutureMinimumPaymentsNetOfSubleaseRentalsDueInFourYears	5868	USD
CY2018Q4	trov	Operating Leases Future Minimum Payments Net Of Sublease Rentals Due In Three Years OperatingLeasesFutureMinimumPaymentsNetOfSubleaseRentalsDueInThreeYears	968165	USD
CY2018Q4	trov	Operating Leases Future Minimum Payments Net Of Sublease Rentals Due In Two Years OperatingLeasesFutureMinimumPaymentsNetOfSubleaseRentalsDueInTwoYears	941670	USD
CY2018Q1	trov	Preferred Stock Dividend Accrued PreferredStockDividendAccrued	6060	USD
CY2019Q1	trov	Preferred Stock Dividend Accrued PreferredStockDividendAccrued	6060	USD
CY2018Q1	trov	Stock Issued During Period Value Warrants Exercised Net StockIssuedDuringPeriodValueWarrantsExercisedNet	1449167	USD
CY2019Q1	trov	Stock Issued During Period Value Warrants Exercised Net StockIssuedDuringPeriodValueWarrantsExercisedNet	3282266	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	664840	USD
CY2019Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	466747	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	167755	USD
CY2019Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	115676	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1813842	USD
CY2019Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2021737	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2110061	USD
CY2019Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1266407	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	202267605	USD
CY2019Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	207652843	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1406131	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	200067	USD
CY2018Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1406131	USD
CY2019Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	200067	USD
CY2018Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	367223	shares
CY2019Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3735269	shares
CY2018Q4	us-gaap	Assets Assets	14172496	USD
CY2019Q1	us-gaap	Assets Assets	14533200	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	12765265	USD
CY2019Q1	us-gaap	Assets Current AssetsCurrent	12336480	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8225764	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6657158	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11453133	USD
CY2019Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11330079	USD
CY2018Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	3649341	shares
CY2019Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	3302093	shares
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	486636	USD
CY2019Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2019Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3831880	shares
CY2019Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4525354	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3831880	shares
CY2019Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4525354	shares
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	7742	USD
CY2019Q1	us-gaap	Common Stock Value CommonStockValue	7906	USD
CY2018Q1	us-gaap	Cost Of Revenue CostOfRevenue	366344	USD
CY2019Q1	us-gaap	Cost Of Revenue CostOfRevenue	0	USD
CY2019Q1	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	0	USD
CY2018Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1090671	USD
CY2019Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	0	USD
CY2018Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	252480	USD
CY2019Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	45911	USD
CY2018Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	32315	USD
CY2019Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	42076	USD
CY2018Q1	us-gaap	Dividends Preferred Stock DividendsPreferredStock	6060	USD
CY2019Q1	us-gaap	Dividends Preferred Stock DividendsPreferredStock	6060	USD
CY2018Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.23
CY2019Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.02
CY2018Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-6.23
CY2019Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.02
CY2018Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2019Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	800	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	50958	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3635	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-72674	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-52079	USD
CY2018Q1	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	79586	USD
CY2019Q1	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	0	USD
CY2018Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	0	USD
CY2019Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-15725	USD
CY2018Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-97684	USD
CY2019Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-179691	USD
CY2018Q1	us-gaap	Interest Expense InterestExpense	24236	USD
CY2019Q1	us-gaap	Interest Expense InterestExpense	0	USD
CY2018Q1	us-gaap	Interest Income Operating InterestIncomeOperating	21771	USD
CY2019Q1	us-gaap	Interest Income Operating InterestIncomeOperating	64743	USD
CY2018Q1	us-gaap	Interest Paid InterestPaid	16417	USD
CY2019Q1	us-gaap	Interest Paid InterestPaid	0	USD
CY2019Q1	us-gaap	Lessee Leasing Arrangements Operating Leases Renewal Term LesseeLeasingArrangementsOperatingLeasesRenewalTerm	P5Y
CY2019Q1	us-gaap	Lease Cost LeaseCost	94525	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2533233	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	3423	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	5868	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	968165	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	941670	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	614107	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	216774	USD
CY2019Q1	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	233187	USD
CY2019Q1	us-gaap	Lessor Operating Lease Payments To Be Received Five Years LessorOperatingLeasePaymentsToBeReceivedFiveYears	0	USD
CY2019Q1	us-gaap	Lessor Operating Lease Payments To Be Received Four Years LessorOperatingLeasePaymentsToBeReceivedFourYears	0	USD
CY2019Q1	us-gaap	Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear	233187	USD
CY2019Q1	us-gaap	Lessor Operating Lease Payments To Be Received Three Years LessorOperatingLeasePaymentsToBeReceivedThreeYears	0	USD
CY2019Q1	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	0	USD
CY2018Q4	us-gaap	Liabilities Liabilities	4088304	USD
CY2019Q1	us-gaap	Liabilities Liabilities	4847019	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14172496	USD
CY2019Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14533200	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2965318	USD
CY2019Q1	us-gaap	Liabilities Current LiabilitiesCurrent	3284730	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-1568606	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-123054	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	1292641	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	3242266	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-5100	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-5274	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-2856147	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-3360046	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-4786177	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-3904771	USD
CY2018Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4792237	USD
CY2019Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4179100	USD
CY2018Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-4792237	USD
CY2019Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-4179100	USD
CY2018Q1	us-gaap	New Accounting Pronouncement Or Change In Accounting Principle Effect Of Adoption Quantification NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification	109922	USD
CY2018Q1	us-gaap	Operating Expenses OperatingExpenses	4755159	USD
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	4123721	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4655023	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3961763	USD
CY2019Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	194462	USD
CY2019Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	2316459	USD
CY2019Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	2503000	USD
CY2018Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	USD
CY2019Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	796246	USD
CY2018Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2019Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1520213	USD
CY2019Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	226364	USD
CY2018Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	USD
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1816286	USD
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1970000	USD
CY2019Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.065
CY2019Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term OperatingLeaseWeightedAverageRemainingLeaseTerm	P2Y9M4D
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	2833666	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	914540	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	3423	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	5868	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	968165	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	941670	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Receivable OperatingLeasesFutureMinimumPaymentsReceivable	333124	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Receivable Current OperatingLeasesFutureMinimumPaymentsReceivableCurrent	333124	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Receivable In Five Years OperatingLeasesFutureMinimumPaymentsReceivableInFiveYears	0	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Receivable In Four Years OperatingLeasesFutureMinimumPaymentsReceivableInFourYears	0	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Receivable In Three Years OperatingLeasesFutureMinimumPaymentsReceivableInThreeYears	0	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Receivable In Two Years OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears	0	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	102798	USD
CY2019Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	87073	USD
CY2018Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1000	USD
CY2019Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2010	USD
CY2018Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5100	USD
CY2019Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5274	USD
CY2018Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	6060	USD
CY2019Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	6060	USD
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2019Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	60	USD
CY2019Q1	us-gaap	Preferred Stock Value PreferredStockValue	260	USD
CY2018Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1144377	USD
CY2019Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	890725	USD
CY2018Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0	USD
CY2019Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-40000	USD
CY2018Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1449167	USD
CY2019Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	3282266	USD
CY2019Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	3300000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3414494	USD
CY2019Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1559768	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1304433	USD
CY2019Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	293361	USD
CY2018Q1	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	156526	USD
CY2018Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1406131	USD
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	200067	USD
CY2018Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	971488	USD
CY2019Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	188984	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	-40000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	6506107	USD
CY2019Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-196370315	USD
CY2019Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2503148	USD
CY2018Q1	us-gaap	Royalty Revenue RoyaltyRevenue	49055	USD
CY2019Q1	us-gaap	Royalty Revenue RoyaltyRevenue	62021	USD
CY2018Q1	us-gaap	Sales Revenue Net SalesRevenueNet	100136	USD
CY2019Q1	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	0	USD
CY2018Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	1883838	USD
CY2019Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	2648599	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-192191215	USD
CY2019Q1	us-gaap	Sales Revenue Net SalesRevenueNet	161958	USD
CY2018Q1	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	51081	USD
CY2019Q1	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	99937	USD
CY2018Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2504977	USD
CY2019Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1475122	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	4679090	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	10084192	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	9686181	USD
CY2019Q1	us-gaap	Sublease Income SubleaseIncome	99937	USD
CY2018Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-129689	USD
CY2019Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-9761	USD
CY2018Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	768951	shares
CY2019Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4086561	shares
CY2018Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	768951	shares
CY2019Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4086561	shares

Files In Submission

Name	View Source	Status
0001628280-19-006051-index-headers.html	Edgar Link	pending
0001628280-19-006051-index.html	Edgar Link	pending
0001628280-19-006051.txt	Edgar Link	pending
0001628280-19-006051-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
trov-033119exhibit311.htm	Edgar Link	pending
trov-033119exhibit312.htm	Edgar Link	pending
trov-033119exhibit321.htm	Edgar Link	pending
trov-033119exhibit322.htm	Edgar Link	pending
trov-033119x10q.htm	Edgar Link	pending
trov-20190331.xml	Edgar Link	completed
trov-20190331.xsd	Edgar Link	pending
trov-20190331_cal.xml	Edgar Link	unprocessable
trov-20190331_def.xml	Edgar Link	unprocessable
trov-20190331_lab.xml	Edgar Link	unprocessable
trov-20190331_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CRDF
Cardiff Oncology, Inc. Stock $crdf

2019 Q1 Form 10-Q Financial Statement

#000162828019006051 Filed on May 07, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRDF Cardiff Oncology, Inc. Stock $crdf

2019 Q1 Form 10-Q Financial Statement

#000162828019006051 Filed on May 07, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRDF
Cardiff Oncology, Inc. Stock $crdf